April 5, 2013
/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), announced that it has filed its 2012 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on
April 5, 2013
. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended
December 31, 2012
Form 20-F can be accessed electronically through the Grifols website at
. The Form 20-F is also available on the SEC's website at
Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at
to the attention of Grifols's Investor Relations, Re: 2012 Annual Report on Form 20-F.
Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.
As the third largest global producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in
and employs more than 11,000 people worldwide.
In 2012, Grifols' sales exceeded
2,620 million euros
. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit